STERIS plc
STERIS plc
Your view on STE
Overview
What the company does, where it operates, and who runs it.
About STERIS plc
- Industry
- Medical - Specialties
- Sector
- Healthcare
- CEO
- Daniel A. Carestio
- Headquarters
- 70 Sir John Rogerson's Quay, Dublin, IE
- Industry
- Medical - Specialties
- Sector
- Healthcare
- CEO
- Daniel A. Carestio
- Headquarters
- 70 Sir John Rogerson's Quay, Dublin, IE
STERIS plc provides infection prevention and other procedural products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental.
The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; accessories for gastrointestinal (GI) procedures, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.
It also provides capital equipment installation, maintenance, upgradation, repair, and troubleshooting services; preventive maintenance programs and repair services; instrument and endoscope repair and maintenance services; and custom process improvement consulting and outsourced instrument sterile processing services.
The Applied Sterilization Technologies segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers through a network of approximately 50 contract sterilization and laboratory facilities.
The Life Sciences segment designs, manufactures and sells consumable products, such as formulated cleaning chemistries, barrier and sterility assurance products, steam and vaporized hydrogen peroxide sterilizers, and washer disinfectors.
This segment also offers equipment installation, maintenance, upgradation, repair, and troubleshooting services; and preventive maintenance programs and repair services. The Dental segment provides hand and powered dental instruments, infection control products, personal protective equipment, and water quality products for dental suite.
The company serves its products and services to hospitals, other healthcare providers, and pharmaceutical manufacturers. The company was founded in 1985 and is based in Dublin, Ireland.
Stock Data
Price chart, volume, and trading data.
What moved it
FRC Fair Value Algorithm
What the FRC Fair Value algorithm says it is worth vs. the current price — FRC's own, on every stock.
About this section
Fair value for STERIS plc from FRC's valuation model, read against the market price. STE last traded at $261.91, 31.0× trailing earnings — the estimate is read against that market price. The model runs on every stock on the platform and shows the estimate per share and the date it was calculated. A free account covers 3 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for STERIS plc. Starting points for STERIS plc: P/E 31.0, EPS $8.50, beta 0.86 — an Medical - Specialties name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for STERIS plc. STERIS plc paid $2.58 per share over the last year — a 1.0% yield at the current $261.91 price. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for STERIS plc. Trailing twelve-month EPS for STERIS plc stands at $8.50. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Wall Street Analyst Estimates
Analysts' price targets, ratings, and revenue and EPS estimates.
Price targets, ratings and estimates published by outside analysts. Not FRC research, not a recommendation, and not the FRC Fair Value: that is FRC's proprietary model, built on the cash a company generates.
Current price
—
live quote
Analysts' target
$279.75
average of 4 firms, last 12 months
Analyst Ratings
- Strong Buy0
- Buy3
- Hold0
- Sell0
- Strong Sell0
Earnings Estimate
| EPS | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Mar 2027 | Next YearFY Mar 2028 |
|---|---|---|---|---|
| Avg. estimate | $2.79 | $3.14 | $11.45 | $12.44 |
| Low estimate | $2.77 | $3.11 | $11.25 | $12.28 |
| High estimate | $2.84 | $3.17 | $11.66 | $12.68 |
| No. of analysts | 4 | 4 | 5 | 5 |
| Year-ago EPS | $2.53 | $2.83 | $7.93 | — |
| Growth | +10.3% | +11.0% | +44.4% | — |
Revenue Estimate
| Revenue | Current QtrDec 2026 | Next QtrMar 2027 | Current YearFY Mar 2027 | Next YearFY Mar 2028 |
|---|---|---|---|---|
| Avg. estimate | $1.60B | $1.71B | $6.39B | $6.82B |
| Low estimate | $1.59B | $1.70B | $6.38B | $6.75B |
| High estimate | $1.62B | $1.73B | $6.42B | $6.98B |
| No. of analysts | 4 | 4 | 6 | 6 |
| Year-ago revenue | $1.50B | $1.59B | $5.94B | — |
| Growth | +7.0% | +7.4% | +7.6% | — |
Source: Wall Street analysts' published price targets, ratings and estimates, compiled by Financial Modeling Prep from StreetInsider; as of Nov 18, 2026. Not FRC research or a recommendation.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for STERIS plc. STERIS plc has reported as a listed company since 1992. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Peer companies
Market cap
- CNVVFConvaTec Group PlcMedical - Instruments & Supplies$7.1B
- GNGBYGetinge AB (publ)Medical - Devices$6.1B
- MLABMesa Laboratories, Inc.Medical - Specialties$754M
- SDMHFSartorius Stedim Biotech S.A.Medical - Instruments & Supplies$21.2B
- SHCSotera Health CompanyMedical - Diagnostics & Research$4.6B
More Medical - Specialties companies
- WOKWORK Medical Technology Group Ltd.NASDAQ$5M
- YPHDFYpsomed Holding AGOTC$5.2B
- ACAISafeplus International Holdings LimitedOTC$477
- ADLIAmerican Medical Technologies Inc.OTC$1,031
- AIMVAI Maverick Intel, Inc.OTC$3M
- ALCAlcon Inc.NYSE$35.4B
- ANIKAnika Therapeutics, Inc.NASDAQ$173M
- APYXApyx Medical CorporationNASDAQ$112M
- ASFXAmerican Scientific Resources, IncorporatedOTC$7,001
- AVTIAvitar, Inc.OTC$1,382
- BEATHeartBeam, Inc.NASDAQ$20M
- BEATWHeartBeam, Inc.NASDAQ$7M
ETFs holding STERIS plc
% of the fund
- VOOVanguard S&P 500 ETF$1.0T in assets0.03%
- VTIVanguard Total Stock Market ETF$689.2B in assets0.03%
- VOVanguard Mid-Cap ETF$103.4B in assets0.21%
- IVViShares Core SP 500 ETF$852.9B in assets0.04%
- IHIiShares US Medical Devices ETF$4.0B in assets3.18%
- CSMDCongress SMID Growth ETF$481M in assets2.67%
- NUMVNuveen ESG Mid-Cap Value$427M in assets1.82%
- FXHFirst Trust Health Care AlphaDEX Fund$1.2B in assets1.58%
Largest holders first, then the funds most concentrated in STE.
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold STERIS plc, and how their positions are changing. At a $25.43B market value, institutional positions materially move STERIS plc's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by STERIS plc executives and directors. Shares of STERIS plc have traded between $200.98 and $268.30 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
Senate Trading
U.S. Senator disclosures filed under the STOCK Act.
About this section
U.S. Senate disclosures naming STERIS plc. STERIS plc is a $25.43B Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely.
House Trading
U.S. Representative disclosures filed under the STOCK Act.
About this section
U.S. House of Representatives disclosures naming STERIS plc. Representatives' reported transactions in this security, shown next to the company's fundamentals.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for STERIS plc. Coverage tracks STERIS plc within Medical - Specialties (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of STERIS plc.